The CEO of pharmaceutical giant Sanofi, Paul Hudson, has staked his career on the company’s ability to bring AI-discovered drugs to market by 2025. Hudson believes that AI will revolutionize drug discovery, reducing the time and cost required to develop new treatments. Sanofi has invested heavily in AI and machine learning, partnering with companies like Recursion and Exscientia. The goal is to use AI to analyze vast amounts of data and identify promising drug candidates more efficiently than traditional methods. However, Hudson acknowledges the risks, stating that if Sanofi fails to deliver AI-discovered drugs by 2025, his “career is at stake.” The pharmaceutical industry has been slow to adopt AI due to regulatory hurdles and skepticism about its capabilities. Sanofi’s ambitious timeline puts pressure on the company to overcome these challenges and demonstrate the transformative potential of AI in drug development.